Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Current Liabilities for the year ending June 30, 2024

Kazia Therapeutics Limited Current Liabilities is NA for the year ending June 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Kazia Therapeutics Limited Current Liabilities for the year ending June 30, 2023 was USD 5.03 M, a 55.70% change year over year.
Kazia Therapeutics Limited Current Liabilities for the year ending June 30, 2022 was USD 3.23 M, a -48.21% change year over year.
Kazia Therapeutics Limited Current Liabilities for the year ending June 30, 2021 was USD 6.24 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years